EU/3/18/2085

About

On 19 November 2018, orphan designation (EU/3/18/2085) was granted by the European Commission to Rigenerand S.r.l., Italy, for autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (also known as RR001) for the treatment of pancreatic cancer.

Key facts

Active substance
autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
Disease / condition
The treatment of pancreatic cancer
Date of decision
19/11/2018
Outcome
Positive
Orphan decision number
EU/3/18/2085

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Rigenerand S.r.l.
Via Maestri del Lavoro, n.4
41036 Medolla (MO)
Italy
Tel. +3905351876172

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating